Categories
Marijuana

CV Sciences Inc. (OTCMKTS:CVSI) To File Request For Continued Examination of Its 15/426,617 Patent Application

CV Sciences Inc. (OTCMKTS:CVSI) has announced that it plans to submit a Request of Continued Examination of its 15/426,617 patent application with the US Patent Trademark Office. The patent is titled Pharmaceutical Formulations Containing Cannabidiol and Nicotine For Treating Smokeless Tobacco Addiction.

Filing for an RCE

The intention to file for a Request of Continued Examination comes after the USPTO notified CV Sciences that the Patent Trial and Appeal Board declined their appeal to reverse the decision of the examiner to deny specific claims that were made in the company’s patent application.

The Chief Executive Officer of CV Sciences, Joseph Dowling, stated that the decision of USPTO was disappointing. It was important to note that it was not the end of the process. He added that the company plans to make the request continued examination. He said that they are confident in the protection of the company’s intellectual property regarding the formulation as well as the ability of CV Sciences to commercialize the invention.

Dowling indicated that they believe the innovation will offer a solution to the persistent epidemic in smokeless tobacco addiction. He added that the company would remain focused on the development of proprietary products that can enhance the quality of life of its customers.

PlusCBD Oil leading product in the CBD market

CV Sciences runs two different business segments which are consumer product divisions and the drug development division. The consumer division focuses on manufacturing, selling, and marketing of their CBD products to different markets. The drug development segment focuses on the development and commercialization of innovative CBD-based therapeutics, that utilize CBD.

The company’s PlusCBD oil is top-selling hemp-derived CBD product, and according to the CEO, consumers choose the product because of its quality, purity, and consistency. Dowling indicates that the company offers a premium product line of gluten-free and non-GMO full spectrum CBD products in the market. CV Science’s full-spectrum hemp extracts are produced, tested, and processed in the company’s state of the art facility, to ensure products conform to its standards.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

CV Sciences Inc. (OTCMKTS:CVSI) Enters Distribution Partnership With Southeastern Grocers

Pin It on Pinterest